Nervosave Therapeutics
NVO-101 / CMT1A

Targeting the genetic driver of CMT1A

Our lead investigational gene therapy program aims to reduce excess PMP22 expression through localized perineural AAV delivery.

Peripheral nerve illustration
Program overview

The challenge

Charcot–Marie–Tooth disease type 1A (CMT1A) is an inherited peripheral neuropathy associated with increased PMP22 gene dosage. It can progressively affect sensation, strength and mobility.

Our investigational approach

NVO-101 uses an AAV9-based vector designed to express an RNA-interference payload targeting PMP22 in Schwann cells. Perineural administration is intended to reach the targeted nerve while limiting systemic exposure.

Development status

Preclinical research has supported the rationale for this approach. The program is being advanced toward clinical evaluation; safety and efficacy in people have not been established.

At a glance

Program focus

  • Inherited neuropathy
  • PMP22-focused RNA interference
  • Local perineural delivery
  • Clinical development planned

Investigational research program. Preclinical observations do not demonstrate clinical safety or efficacy.

Collaborate with Nervosave

Advance nerve health innovation

We welcome conversations with scientific, clinical and strategic partners.